News Releases

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 20, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH)

Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum Mont-Saint-Guibert, Belgium – May 20, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company

REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio reimbursement in the U.S. Mont-Saint-Guibert, Belgium – May 12, 2026, 10:05pm CET /

REGULATED INFORMATION May 8, 2026, 10:05pm CET / 4:05pm ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “ Company ”) Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June

Nyxoah to Participate in the Bank of America 2026 Healthcare Conference Mont-Saint-Guibert, Belgium – April 30, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of

Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026 Mont-Saint-Guibert, Belgium – April 28, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA)

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces

REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales Foundation Established to Drive Significant Growth in 2026 Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET /

REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), March 13, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces

Nyxoah to Participate in the Oppenheimer 36 th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 11, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development